FDA offers guidance on labeling mutation risks of ingredients; Accuratus gets CMC operation;

> The FDA has issued guidance on the need for drugmakers to assess and label the risks of impurities in drugs to create DNA mutations that might lead to cancer. Guidance

> Accuratus Lab Services has acquired Array BioPharma's chemistry, manufacturing and controls (CMC) operation to expand its its CDMO services. Report

> An FDA advisory committee next month will evaluate post marketing studies of the use and abuse of the new abuse deterrent formulation of Oxycontin ER. Report

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.